Literature DB >> 22403182

Canakinumab induces remission in a patient with resistant familial Mediterranean fever.

Duygu Ovunc Hacihamdioglu1, Seza Ozen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22403182     DOI： 10.1093/rheumatology/kes021

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  14 in total

Review 1.  The myths we believed in familial Mediterranean fever: what have we learned in the past years?

Authors:  Seza Ozen; Ezgi Deniz Batu
Journal:  Semin Immunopathol       Date:  2015-04-02       Impact factor: 9.623

2.  Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.

Authors:  Fehime Kara Eroglu; Nesrin Beşbaş; Rezan Topaloglu; Seza Ozen
Journal:  Rheumatol Int       Date:  2015-05-23       Impact factor: 2.631

3.  Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.

Authors:  Tolga Yildirim; Rahmi Yilmaz; Muge Uzerk Kibar; Yunus Erdem
Journal:  J Nephrol       Date:  2018-02-14       Impact factor: 3.902

Review 4.  IL-1β biological treatment of familial Mediterranean fever.

Authors:  Alessandra Soriano; Elena Verecchia; Antonella Afeltra; Raffaele Landolfi; Raffaele Manna
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

Review 5.  Colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Peter L Thompson
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113

Review 6.  Targeting interleukin-1 in heart disease.

Authors:  Benjamin W Van Tassell; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Circulation       Date:  2013-10-22       Impact factor: 29.690

Review 7.  A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin.

Authors:  Seza Ozen; Yelda Bilginer
Journal:  Nat Rev Rheumatol       Date:  2013-11-19       Impact factor: 20.543

Review 8.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 9.  Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Francesco Caso; Isabella Muscari; Flora Magnotti; Maria Giuseppina Brizi; Susanna Guerrini; Maria Patti; Leonardo Punzi; Mauro Galeazzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

Review 10.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.